Cancer-associated ThrombosisNCT07388056
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
An observational study of Cancer-associated Thrombosis, run by Thammasat University.
Trial summary
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is: Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer-associated Thrombosis
- What is being tested?
- Anticoagulant
- How many people
- 169 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2012to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated at Thammasat University Hospital or Panyananthaphikkhu Chonprathan Medical Center.
Who may be able to join
- Adult patients aged ≥18 years
- Histopathologically confirmed cancer
- Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)
- Received anticoagulation therapy for at least six months Exclusion Criteria
- Patients who do not meet the inclusion criteria
Who cannot join
None listed.
About this study
Official title: Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:
- Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.
Read the detailed description
Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion.
Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.
- Conditions
- Cancer-associated Thrombosis
- Being tested
- Anticoagulant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AnticoagulantDrug
warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC
| Study group | Role | What they receive |
|---|---|---|
| Therapeutic dose anticoagulant group | including patients with the standard therapeutic dose-administered after the initial six-month treatment period. Receives: Drug: Anticoagulant | |
| Prophylactic dose anticoagulant group | including patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period. Receives: Drug: Anticoagulant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrent thrombosis
cumulative incidence of recurrent thrombosis
Measured: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.
Secondary outcomes (2)
Anticoagulant related bleeding
cumulative incidence of bleeding
Measured: After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.
Overall survival
Overall survival
Measured: The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Jan 2012
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer-associated ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 169 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thammasat University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lantarima Bhoopat, Thammasat University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07388056
- Sponsor's protocol ID
- MTU-EC-IM-1-301/65
- Status last verified
- Jan 2026
- First submitted
- 21 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.
- ClinicalTrials.gov ID
- NCT07388056
- Acronym / sponsor ID
- MTU-EC-IM-1-301/65
- Conditions
- Cancer-associated Thrombosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 169 participants (actual)
- Lead sponsor
- Thammasat UniversityUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:
- Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.
Detailed description
Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion.
Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Therapeutic dose anticoagulant group | – | Drug: Anticoagulantincluding patients with the standard therapeutic dose-administered after the initial six-month treatment period. |
| Prophylactic dose anticoagulant group | – | Drug: Anticoagulantincluding patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated at Thammasat University Hospital or Panyananthaphikkhu Chonprathan Medical Center.
Key inclusion criteria (5 listed)
- Adult patients aged ≥18 years
- Histopathologically confirmed cancer
- Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)
- Received anticoagulation therapy for at least six months Exclusion Criteria
- Patients who do not meet the inclusion criteria
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anticoagulantwarfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC | Drug | Prophylactic dose anticoagulant group, Therapeutic dose anticoagulant group |
Primary outcome
Recurrent thrombosis
Time frame: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.
cumulative incidence of recurrent thrombosis
2 secondary outcomes
Anticoagulant related bleeding
Time frame: After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.
Overall survival
Time frame: The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer-associated Thrombosis
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
RecruitingPhase 4
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Cancer-associated Thrombosis, Thrombocytopenia
RecruitingObservational study
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
Cancer-associated Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer-associated Thrombosis, run by Thammasat University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrent thrombosis (time frame: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026; AzTrials last refreshed its copy on 8 Nov 2026.